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Abstract
Motor neurons containing aggregates of superoxide dismutase 1 (SOD1) are hallmarks of amyotrophic lateral sclerosis (ALS) 
caused by mutations in the gene encoding SOD1. We have previously reported that two strains of mutant human (h) SOD1 
aggregates (denoted A and B) can arise in hSOD1-transgenic models for ALS and that inoculation of such aggregates into 
the lumbar spinal cord of mice results in rostrally spreading, templated hSOD1 aggregation and premature fatal ALS-like 
disease. Here, we explored whether mutant hSOD1 aggregates with prion-like properties also exist in human ALS. Aggre-
gate seeds were prepared from spinal cords from an ALS patient carrying the hSOD1G127Gfs*7 truncation mutation and from 
mice transgenic for the same mutation. To separate from mono-, di- or any oligomeric hSOD1 species, the seed preparation 
protocol included ultracentrifugation through a density cushion. The core structure of hSOD1G127Gfs*7 aggregates present in 
mice was strain A-like. Inoculation of the patient- or mouse-derived seeds into lumbar spinal cord of adult hSOD1-expressing 
mice induced strain A aggregation propagating along the neuraxis and premature fatal ALS-like disease (p < 0.0001). Inocula-
tion of human or murine control seeds had no effect. The potencies of the ALS patient-derived seed preparations were high 
and disease was initiated in the transgenic mice by levels of  hSOD1G127Gfs*7 aggregates much lower than those found in the 
motor system of patients carrying the mutation. The results suggest that prion-like growth and spread of hSOD1 aggregation 
could be the primary pathogenic mechanism, not only in hSOD1 transgenic rodent models, but also in human ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by 
adult-onset degeneration of the upper and lower motor neu-
rons. The paresis begins focally and spreads to adjacent 
myotomes, suggesting an early initial event in one motor 
unit followed by contiguous spread of the disease process 
[9]. The result is progressive paresis and inevitably death 
when the respiratory muscles become paralyzed. Mutations 
in the gene encoding the ubiquitously expressed cytosolic 
enzyme superoxide dismutase 1 (SOD1) cause ALS [32], 
and are found in 1–9% of patients [1]. To date, over 200 
mutations in SOD1 have been found in patients with ALS 
[37] (http://alsod .iop.kcl.ac.uk/). Most of them are missense 
among the 153 amino acids (aa) in the subunits of the SOD1 
homodimer, but 23 cause long C-terminal truncations which 
preclude native folding. This suggests that any common 
ALS-inducing SOD1 species must be misfolded.
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Neuronal inclusions containing aggregated SOD1 are a 
hallmark of ALS, both in patients and in transgenic (Tg) ani-
mal models expressing mutant human SOD1 s (hSOD1) [24]. 
We recently reported that two structurally different strains of 
aggregates (A and B) can arise in spinal cords of mice express-
ing full-length human SOD1 (hSOD1) variants [6]. They were 
different from hSOD1 aggregates generated under a variety 
of conditions in vitro, showing that the conditions in the CNS 
shape the aggregation process. Inoculation of strain A or B 
hSOD1 aggregates into spinal cord of asymptomatic mice 
expressing a hSOD1 transgene triggered spreading templated 
hSOD1 aggregations and early-onset fatal ALS-like disease 
[7]. Seeding effects of whole homogenates of spinal cords 
from end-stage Tg mice have also been reported [4, 5]. More-
over, homogenates from two patients carrying the hSOD1A4V 
mutation have been found to induce aggregation of yellow 
fluorescent protein-fused  hSOD1G85R in spinal cord slices from 
Tg mice [3]. Finally, homogenates of spinal cords from ALS 
patients carrying several different hSOD1 mutations have been 
found to trigger increased aggregation of green fluorescent 
protein-fused hSOD1 mutants expressed in human embryonal 
kidney cells [31]. These findings suggest that a prion-like dis-
ease transmission could be the primary pathogenic mechanism 
of SOD1-induced ALS.
To cause ALS-like disease within the short lifes-
pan of mice, the hSOD1 variants have to be expressed at 
rates ~ 20-fold higher than that of the endogenous murine 
SOD1 [17, 18, 21], and the relevance of the murine models 
for human ALS has been questioned [27, 30]. The primary 
goal of the present investigation was to determine whether 
hSOD1 aggregates with prion-like properties also are pre-
sent in the spinal cord of humans with ALS.
Autopsy material from a patient carrying the 
p.G127Gfs*7 (alias “G127X”) SOD1 truncation mutation 
was used for the study [2]. The choice was based on our pre-
vious finding of comparatively large amounts of aggregates 
in ventral horns from ALS patients carrying that mutation 
[19, 20]. Aggregates formed in spinal cords of  hSOD1G127X 
Tg ALS model mice were found to have a strain A-like core 
structure. Inoculation of both murine and human  SOD1G127X 
aggregates into spinal cords of mice expressing a hSOD1 
transgene caused spreading strain A aggregation and aggres-
sive premature fatal motor neuron disease, demonstrating 
for the first time the presence of hSOD1 aggregates with 
prion-like properties in human ALS.
Materials and methods
Patient and control
The family carrying the hSOD1G127X mutation has been 
described [2]. At the age of 71 years, the patient developed 
symptoms of muscle weakness beginning in the truncal mus-
cles. Following a typical progressive disease course ending 
with tetraparalysis and general wasting of skeletal muscles, 
he died 2 years later. The patient displayed both upper and 
lower motor neuron signs but no atypical features, was not 
cognitively impaired and did not suffer from other relevant 
diseases. There was no other hereditary predisposition than 
ALS, in particular not for Creutzfeldt–Jakob disease. The 
control patient suffered from epilepsy and died of an acute 
myocardial infarction at the age of 73 years. With informed 
consent from both patients and the next of kin, tissue was 
saved and immediately frozen at − 80 °C. The post-mor-
tem times were 26 and 29.5 h, respectively. The study was 
approved by the Research Ethics Committee at Umeå Uni-
versity as well as the Umeå Regional Ethical Review Board 
and adhered to the principles of the Declaration of Helsinki.
Mice
Hemizygous Tg mice that express  hSOD1G85R (line 148) 
were used as recipients for the inoculations [8]. The lifespan 
of this mouse line is 397 ± 49 days (n = 101) in our labora-
tory. There are no differences between the sexes: the lifes-
pans of the females were 398 ± 60 days (n = 31) and of the 
males 397 ± 44 days (n = 70). For preparation of the strain B 
seed, hSOD1D90A Tg mice were used [23]. The hSOD1G127X 
Tg mouse strain was generated in house, and was homozy-
gous for the transgene insertion [20]. The mouse strains 
were backcrossed > 30 generations in C57BL/6 mice. The 
use and maintenance of the mice and the experimental pro-
tocol described in this article were approved by the Umeå 
Regional Animal Research Ethical Board.
Preparation of hSOD1 aggregate seeds 
by centrifugation through density cushion
Strain A, strain B and control seeds were prepared from spi-
nal cords from end-stage spinal cords of hSOD1G85R and 
hSOD1D90A Tg mice and from a 100-day-old non-transgenic 
C57BL/6 mouse, respectively. A seed was likewise prepared 
from two end-stage hSOD1G127X Tg mice. Human-derived 
seeds were prepared from lumbar ventral horn specimen 
(lamina IX) dissected from the  hSOD1G127X patient and the 
control.
Briefly, the protocol involved homogenization in 25 vol-
umes of PBS containing 1% NP40 and 1 M guanidinium 
chloride using an Ultraturrax and sonication [7]. After 
clearing by a 1000×g centrifugation, the homogenates 
were layered on top of a 4 cm high 13% iohexol cushion 
(δ = 1.074) and centrifuged at 175,000×g for 1 h. Under 
these conditions, proteinous components with molecular 
masses > ~ 5 × 106 Da will be sedimented into the pellets 
[34]. The seeds will, therefore, not contain monomeric, 
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dimeric or any oligomeric hSOD1 species. The pellets 
were suspended by sonication in a small volume of PBS 
and stored in aliquots at − 80 °C. The mouse  hSOD1G85R 
and  hSOD1G127X seeds contained both 3 ng/µl (mutant) 
hSOD1. The total protein contents of the mouse  hSOD1G85R, 
 hSOD1G127X and control seeds were 207 ng/µl, 385 ng/µl and 
220 ng/µl, respectively.
A second seed (II) was prepared from the same 
hSOD1G127X-carrying patient using a subsequent modified 
protocol. 0.5 M guanidinium chloride was used instead of 
1 M, and following sonication, the homogenate was diluted 
with 3.33 volumes water with 1% NP40 to achieve physi-
ological ionic strength. Thereafter, it was sonicated again, 
loaded on top of the 4 cm density cushion and subjected 
to ultracentrifugation. Characterization of the human 
 hSOD1G127X seeds I and II, and the human control seed 
(prepared by protocol I) is shown in Supplementary Fig. S2.
Inoculation of the hSOD1 aggregate seeds 
into lumbar spinal cord and monitoring of mice
The protocol used was somewhat modified compared with 
the previous study [7]. The recipient 100-day-old asympto-
matic hSOD1G85R Tg mice were anesthetized with 5% iso-
fluorane in an induction chamber. The mice were then fixed 
on a small animal stereotactic frame (Kopf Instruments) and 
anesthesia maintained with 1.5–2% isofluorane via a face-
mask. Also, 0.005 µg Rimadyl per gram weight was injected 
s.c. approximately 15 min before starting surgery. Two small 
bilateral, longitudinal cuts on the back close to the spine 
were then made, making pockets for attachment of a sta-
bilizing spine clamp. To reach the spinal cord, a 3–4 mm 
transversal cut through the muscles was made. Inoculation 
was done between two vertebrae after the meninges were 
punctured using a fine needle. The depth of insertion was 
controlled using a digital display console with 10-µm reso-
lution (model 940-B, Kopf). One µl of the seeds was inocu-
lated into the lumbar ventral horn on the left side at the 
L2–L3 levels. A Syringe model 75 RN Neuros with a sharp 
custom syringe (33/78/4)S 30° (Hamilton) was used, and the 
injection velocity was 0.125 µl/min controlled by an infusion 
pump (Legato 130, KD Scientific). The syringe was then 
slowly pulled out, the fascia sutured, and the skin closed 
using Tissue Adhesive (3M Vetbond). The duration of the 
surgical procedures was about 25 min, and in total, the mice 
were under anesthesia for about 40 min. To compensate for 
dehydration and any blood loss, 250 µl physiological NaCl 
was injected subcutaneously. Buprenorphine was injected 
2–3 times at 12-h intervals until the mice were pain free.
No obvious sphincter or other bladder disturbances 
were observed in any of the operated mice, and the sen-
sory response in their hind legs was normal. The mice were 
examined at least every third day, and weighed once a week. 
In the hSOD1 aggregate seed-inoculated mice, the onset was 
uniformly splaying of a hind leg. The mice were considered 
terminally ill when the hind legs were fully or almost fully 
paralyzed. In cases with more prominent foreleg symptoms 
(some control-preparation and non-inoculated Tg mice), 
severe eye infection in combination with severe foreleg 
weakness was the criterion for end-stage disease.
Excluded mice
Seven mice were excluded and not reported in “Results”, 
“Discussion”, figures or the Table 1. One mouse died during 
surgery and another 3 days thereafter. One mouse control 
seed-inoculated mouse was euthanized 59 days after inocula-
tion because of infection, one because of a back wound after 
93 days, and one was found dead in the cage after 153 days, 
probably because of infection. One mouse  hSOD1G127X 
seed-inoculated mouse was found dead of unknown cause 
after 58 days. Finally, a human  hSOD1G127X-I seed-inocu-
lated mouse died with swollen belly after 159 days. None of 
these mice showed any paretic symptoms.
Antibodies
Antibodies to peptides in hSOD1 (corresponding to aas 
4–20, 24–39, 41–49, 43–57, 48–57, 57–72, 80–96, 94–102, 
100–115, 115–121, 131–153, 132–140 and 144–153) that 
were coupled to keyhole limpet hemocyanin were raised 
in rabbits and affinity purified with immobilized peptides 
as described (Ra-Abs) [15, 20]. Antibodies raised to the 
C-terminal end in  hSOD1G127X, aas 111–127GQRWK 
and 123–127 GQRWK, were prepared in the same way. A 
chicken antibody (Ch-Ab) against aas 131–153 was also 
raised and affinity purified. A monoclonal mouse antibody 
(Mo-Ab) against aas 131–153 was produced using standard 
hybridoma technique. For muscle immunohistochemistry, 
an antibody against slow myosin was used (clone NOQ 
7,5,4D; Cat no M8421, Sigma). For motor neuron staining 
and counting, an antibody against choline acetyltransferase 
(ChAT) (abcam EPR 16590) was used.
Tissue homogenization and binary 
epitope‑mapping assay for hSOD1 aggregate 
content and structure
A detailed description of the background to the assay 
and the protocol is found in [6]. The current resolution-
enhanced protocol is based on 15 rabbit antibodies raised 
against short peptides that cover over 90% of the 153 aa 
long hSOD1 subunits (Fig. 1). The reaction of the anti-
bodies with aggregates captured on filter is determined. 
Since the configurational space of short peptides is very 
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large, their randomly induced antibody-eliciting epitopes 
are unlikely to match defined ordered structures in proteins 
and in cores of protein fibrils. The antibodies have been 
found to lack reactivity with natively folded SOD1. In 
943Acta Neuropathologica (2018) 136:939–953 
1 3
contrast, all react avidly with denatured/disordered SOD1, 
in which the corresponding peptide segments can adapt to 
the antigen-binding sites [14, 15]. In reaction with fibrils/
aggregates, the binding of the anti-peptide antibodies is 
essentially “binary”. There is no response to the ordered 
core of protein aggregates/fibrils or to segments other-
wise hidden. Non-recruited sequence elements, which have 
lost their native contacts and therefore are disordered, will 
react with the antibodies.
Usually lumbar, thoracic and cervical spinal cord, 
brainstem, brain (dissected free from midbrain, pons and 
medulla) and cerebellum were analyzed. The dissected 
tissues were homogenized with an Ultraturrax apparatus 
(IKA, Staufen, Germany) for 30 s and by sonication for 
1 min in 25 volumes of ice-cold PBS containing an anti-
proteolytic cocktail (Complete, Roche Diagnostics, Basel, 
Switzerland). The tissue homogenates were added to 20 
volumes of PBS containing 1% NP40, sonicated for 30 s, 
centrifuged at 1000×g for 10 min, and the supernatants 
collected for assay by binary epitope mapping.
Serial 1 + 1 dilutions of the supernatants were captured 
on cellulose acetate filters in a dot-blot apparatus. The 
filters were then cut in slices, incubated with the 15 anti-
bodies and then developed similar to western immuno-
blots. Chemiluminescence of the blots was recorded in 
a ChemiDoc Touch Imaging System (BioRad) and ana-
lyzed with ImageLab software. To allow comparison and 
quantification, one homogenate of spinal cord from an 
end-stage hSOD1G93A Tg mouse, kept frozen in aliquots, 
is designated as a standard (set to 1) and run in one or two 
lanes on all filters and stained with the 57–72 Ra-Ab. For 
an example, see Supplementary Fig. S1. All blots of all 
homogenates with all antibodies were quantified against 
this standard. To facilitate comparison of staining patterns, 
in some cases, the staining intensities of the 15 antibodies 
with individual homogenates were normalized against the 
staining of that homogenate with the 57–72 Ra-Ab (taken 
as 100%).
Quantification of detergent‑resistant hSOD1 
aggregates
Spinal cord plus brain stem from end-stage mice were 
homogenized using an Ultraturrax followed by sonication 
in 25 volumes of PBS containing 1% NP40. Aliquots of 
the homogenates were further diluted 20-fold with NP40-
containing PBS and again sonicated. The homogenates 
were made 3% in iohexol and added to ultracentrifugation 
tubes. PBS was then cautiously layered on top to fill the 
soft ultracentrifugation tubes. Following 2-h centrifugation 
at 175,000×g, the contents of hSOD1 in the pellets were 
determined with western blotting.
Analysis of the total protein content of the seeds
Aliquots of the seed suspensions were mixed with equal 
volumes of 2 × SDS-PAGE sample buffer without glycerol, 
bromophenol blue and reductant and were boiled for 10 min. 
The protein contents were analyzed with the BCA protein 
assay (Pierce) using bovine serum albumin boiled in 1× 
sample buffer as standard.
Immunoblots and quantifications
The western immunoblots were carried out as described 
[20] using antibodies raised in rabbits against peptides in 
the hSOD1 sequence as indicated in the figure legends. 
Chemiluminescence of the blots was recorded in a Chemi-
Doc Touch Imaging System and analyzed with ImageLab 
software (BioRad).
Tissue handling and histopathology
The mice were killed by intraperitoneal injection of pento-
barbital, decapitated and the spinal cords were removed by 
flushing with saline using a syringe inserted distally. The 
cords were then divided sagittally, and typically alternating 
right or left halves were immersion fixed for histopathol-
ogy. Fixed spinal cords were divided into lumbar, thoracic 
and cervical segments, and each segment then cut into six 
parts which were processed as described below. The other 
half was likewise divided into lumbar, thoracic, and cervical 
segments and snap-frozen in − 80 °C for subsequent analysis 
of amounts and structures of hSOD1 aggregates. The brains 
were dissected and divided into right and left hemispheres, 
cerebellum and brainstem, and processed like the spinal 
cords. Fixed tissue was paraffin-embedded, and 4 µm thick 
sections were cut with a microtome (Microm HM400), and 
mounted on glass slides.
For immunohistochemistry, sections were immunostained 
according to the manufacturer’s recommendations using the 
Ventana Benchmark Ultra (Ventana Medical Systems Inc.). 
Fig. 1  Binary epitope-mapping patterns of hSOD1 aggregates in spi-
nal cords from end-stage non-inoculated and inoculated transgenic 
mice. Results for antibodies raised against longer SOD1 peptides 
used in the original protocol are labeled blue, and data for the addi-
tional antibodies raised against shorter peptides are labeled red. The 
aggregates were analyzed in 5 end-stage mice in all groups and the 
standard deviations and means are shown. To facilitate appreciation 
of patterns, all results were normalized against the staining intensity 
with the 57-72 Ra-Ab (= 100%). a and b Non-inoculated hSOD1G85R 
and hSOD1G127X Tg mice, respectively. c–f hSOD1G85R Tg mice inoc-
ulated with indicated seeds
◂
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The sections were preincubated with Ventana Cell Condi-
tioning Solution 2 (CC2) for 8 min followed by 4 min of 
Ventana Protease 1 solution. The primary 131–153 Mo-Ab 
was used at the concentration 1 µg/ml. Incubation time for 
primary antibody was 32 min. The bound primary anti-
bodies were located with corresponding biotin-conjugated 
secondary antibodies coupled to a streptavidin–horserad-
ish peroxidase conjugate and developed using 3,3′diamin-
obenzidine tetrahydrochloride as the precipitating enzyme 
product (brown color) (iView DAB detection kit, Ventana). 
Sections were counterstained with hematoxylin, washed, 
and mounted with Glycergel Mounting Medium (DakoCy-
tomation). Micrographs were taken in a BX53 microscope 
(Olympus) with lamp set at fixed voltage, intensity adjusted 
by standard gray filters using a DP72 camera (Olympus). 
Images were acquired using the Olympus CellSens program 
(version 1.7) with standard settings and white balancing on 
out-of-sections areas.
For immunofluorescence, sections were double immu-
nostained using 131–153 Ch-Ab for detecting SOD1 aggre-
gates and GFAP (Z0334, DakoCytomation) for detecting 
astrocytes. As corresponding fluorescent-labeled secondary 
antibodies, Alexa flour A11039 and A21428 (Invitrogen) 
were used. The sections were examined by confocal laser 
microscopy using a Zeiss LSM 710 confocal microscope and 
were analyzed using the Zen 2011 SP7 software.
Twenty-one end-stage and six early-onset hSOD1G85R Tg 
mice inoculated with the human  hSOD1G127X–I seed and 18 
hSOD1G85R Tg mice inoculated with the human control seed 
were investigated. Furthermore, 13 non-inoculated 300-day-
old and seven non-inoculated 200-day-old hSOD1G85R Tg 
mice were also investigated. In each mouse, sections from 
lumbar, thoracic, and cervical spinal cord, brain stem, cer-
ebellum and brain were examined.
Counting of motor neurons in the spinal cord ventral 
horns was performed on 20 end-stage hSOD1G85R Tg mice 
inoculated with the human-derived  hSOD1G127X I and II 
seeds and 12 non-inoculated hSOD1G85R Tg control mice 
(mean age 300 days). Formalin-fixed paraffin-embedded 
sections as described above were used. The sections were 
stained using an anti- ChAT antibody (Abcam; EPR16590, 
1:750, 32 min incubation time) using the Ventana Bench-
mark Ultra (Ventana Medical Systems Inc.) automatic stain-
ing system and for preincubation we used the CC1 reagent 
(Ventana Medical Systems Inc.). All histological samples 
were whole-slide digitalized using a scanning system (Pan-
noramic 250, Plan-Apochromat, CIS_VCC_F52U25CL). 
Computer graphic analysis was performed with CaseViewer 
software, both from 3D Histotech Ltd., Budapest, Hungary. 
The ImageJ software (http://rsb.info.nih.gov/ij/docs/index 
.html) was used for morphological filtering. The ventral 
horn was defined as the area within the gray-matter border 
and anterior to a frontal plane through the central canal. Cell 
profiles immunopositive for ChAT were identified using the 
ImageJ software and profiles larger than 150 µm2 in this 
region were used in the analysis. As measurement of number 
in each level, the number of profiles for all sections analyzed 
in that segment in each animal (usually four sections in the 
thoracic and cervical segments and six in thoracic segments) 
was divided by the number of sections analyzed. Thus, in 
each mouse, 14 sections were normally analyzed.
Statistics
Unless otherwise indicated in the text, two-sided 
Mann–Whitney U test was used for comparison of two 
groups and for three groups, Kruskal–Wallis test with 
Dunn’s correction was used. A p ≤ 0.05 was considered 
significant.
Results
Human  SOD1G127X aggregates show strain A‑like 
core structure
In the  hSOD1”G127X” mutation, an insertion of 4 nucleo-
tides, tggg, causes an altered reading frame after codon 
G127 leading to the synthesis of a 5 aa long neosequence 
(GQRWK) followed by a premature stop codon [2]. To allow 
the assessment of whether template-directed aggregation 
occurred after the inoculations, the structure of  hSOD1G127X 
aggregates was determined. In the binary epitope-mapping 
assay, the binding of eight polyclonal anti-SOD1 peptide 
Ra-Abs to aggregates captured on a filter is probed [6]. The 
antibodies cover between them 90% of the sequence of the 
protein and only bind to disordered peptide segments [14, 
15]. The ordered core of any fibrils is not seen, but non-
recruited sequence elements that protrude in a disordered 
manner into the solvent will be stained. Since the amounts of 
 hSOD1G127X aggregates in the human ventral horns are min-
ute [20, 21] and CNS from elderly humans produce strong 
obscuring backgrounds, no clear specific patterns appeared 
in the epitope-mapping assay. Therefore, we used spinal 
cords from end-stage hSOD1G127X Tg mice, which contain 
about 30 times more  hSOD1G127X aggregates per unit wet 
weight, to profile the structure (Fig. 1b) [20, 21].
To enhance the resolution of the assay, the eight anti-
bodies in the original protocol (blue columns) were com-
plemented with seven Ra-Abs (red columns) raised against 
shorter hSOD1 peptides (Fig. 1). End-stage non-inoculated 
hSOD1G85R Tg mice displayed typical strain A patterns: the 
N-terminal end recruited to the fibril core; the sequence ele-
ment from ~ aa 45 to ~ aa 90 looping into the solvent; the 
ensuing segment to ~ aa 125 hidden/recruited; and the C-ter-
minal end non-recruited and reactive with antibody. The 
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patterns of aggregates from end-stage hSOD1G127X Tg mice 
were comparable to those of the hSOD1G85R Tg mice from 
the N-terminal to the 100–115 Ra-Ab. Unlike the case of 
 hSOD1G85R aggregates, however, there was a strong reaction 
with the 111–127 GQRWK Ra-Ab. The reactivities with the 
115–121 and 123–127 GQRWK Ra-Abs suggest that this is 
principally due to the neopeptide in  hSOD1G127X aggregates 
being non-recruited and exposed. The patterns, thus, suggest 
that the fibril cores of  hSOD1G85R strain A aggregates and 
 hSOD1G127X aggregates could be equal.
Inoculation of  hSOD1G127X aggregate seeds 
into spinal cord initiates premature fatal motor 
neuron disease
As recipients for the inoculations, we aimed at using Tg 
mice expressing full-length hSOD1s, since they are most 
representative for hSOD1-induced ALS in general, and also 
allow more complete aggregate structure profiling by binary 
epitope mapping. We chose the hSOD1G85R Tg model since 
it displays a uniquely long time window before spontaneous 
hSOD1 aggregation and ensuing paretic disease develops 
(Supplementary Fig. S3). In the protocol used, 1-µl seed 
suspension is inoculated with stereotactic guidance into the 
left ventral horn of lumbar spinal cord of adult 100-day-old 
mice [7].
Whole spinal cords from end-stage hSOD1G127X Tg 
mice and ventral horn specimen from a patient carrying 
the hSOD1G127X mutation were used to prepare seeds. As 
controls, corresponding specimen from non-Tg C57BL/6 
mice and a human dying from cardiovascular disease were 
used. Human  hSOD1G127X seeds were prepared with both the 
original (I) [7], and a subsequent somewhat modified proto-
col (II). The concentration of  hSOD1G127X aggregates in the 
murine seed, 3 ng/µl, was comparable to those in  SOD1G85R 
strain A and  SOD1D90A B seeds previously found to repro-
ducibly transmit aggregation and fatal motor neuron disease 
[7]. The human seeds contained much less: 0.14 and 0.07 ng/
µl (Supplementary Fig. S2). To explore the feasibility of the 
investigation, a dose–response study was carried out with 
a  hSOD1G85R strain A aggregate seed preparation which 
contained 3 ng/µl. Inoculations with 3 and 1 ng, respec-
tively, resulted in essentially equal survival lengths, around 
100 days after inoculation (Fig. 2a). The mice inoculated 
with 0.33 ng lived longer but still significantly shorter than 
non-inoculated hSOD1G85R Tg mice. The difference versus 
those inoculated with the mouse control seed was, however, 
not significant. Further dilution resulted in survivals com-
parable to those of the control groups. This dose–response 
study suggested that there was a marginal chance to reveal 
any prion-like activity in the  hSOD1G127X aggregates in the 
human spinal cord-derived seeds.
Inoculation of the murine  hSOD1G127X seed caused a pre-
mature fatal motor neuron disease with a mean survival of 
86 days, which is comparable to that of mice inoculated with 
the current and previous strain A  hSOD1G85R seeds (Fig. 2a, 
b, Table 1) [7]. Mice inoculated with the human-derived 
 hSOD1G127X I and II seeds lived longer after inoculation, 
Fig. 2  Inoculation of hSOD1 aggregate-containing seeds caused 
premature fatal motor neuron disease. a Inoculation of differ-
ent dilutions of a  hSOD1G85R strain A seed compared with a non-
transgenic control mouse seed. b Inoculation of a human and 
mouse-derived  hSOD1G127X seeds compared with a human con-
trol seed. As references both figures contain survival data for non-
inoculated hSOD1G85R Tg mice (n = 101) subtracted with the mean 
age (102  days) at which the inoculations took place. In a the post-
inoculation survival lengths and significances for differences ver-
sus the mouse control were for the 3, 1, and 0.33  ng inoculations 
107 ± 31  days, p < 0.0001; 85 ± 10  days, p < 0.002; and 301 ± 41, 
p < 0.14 (ns), respectively. The 0.33 ng data were significantly differ-
ent from those of the non-inoculated mice (p < 0.04). For analysis of 
data in b. see Table 1
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216 days and 196 days, respectively, but still significantly 
shorter than mice inoculated with either the human or 
murine control seeds (Fig. 2a, b, Table 1). The survivals of 
two of the mice extended well into the range of the control-
inoculated mice, suggesting that the amounts of  hSOD1G127X 
aggregates in the seeds were close to the limit for reproduc-
ible initiation of motor neuron disease, as could be predicted 
from the dose–response study with the  hSOD1G85R strain A 
seed (Fig. 2a). The  hSOD1G127X aggregates in the human 
seed preparations seemed to be more potent than the strain 
A  hSOD1G85R aggregates in the murine seed.
Around the time of symptom onset, the mice began 
losing weight (Supplementary Fig. S4), which in the end 
stage was around 25% lower than the maxima (Table 1). 
There was fiber-type grouping in skeletal muscle in the 
inoculated Tg mice in the end stage (Fig. 3). Both these 
signs indicate denervation-induced muscle atrophy.
In end-stage human  hSOD1G127X seed-inoculated mice, 
the mean counts of ChAT-positive motor neurons per sec-
tion were, compared with asymptomatic non-inoculated 
 hSOD1G85R Tg mice of the same age (~ 300 days), signifi-
cantly lower in the lumbar, thoracic and cervical segments 
(Table 2). Furthermore, the profile areas (µm2) of the 
remaining motor neurons were also significantly smaller 
in all spinal cord segments (Table 2).
Table 1  Characteristics of the motor neuron disease in inoculated mice
The table shows data for mice predetermined for lifespan analysis. Data are shown as mean ± SD
n.a. not analyzed
Symbols denote significance of differences between  hSOD1G127X and control seeds: ns, p > 0.05; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 
0.0001
A Comparison between the human seeds
B Comparison between the mouse seeds. Amounts of hSOD1 aggregates in end-stage mice were analyzed in pools of spinal cord and brain stem. 
For loss of weights, see also Supplementary Fig. S4
Inoculated seeds
Human Mouse
HSOD1G127X−I hSOD1G127X − II Control hSOD1G127X Control
n n n n n
Age at inoculation (days) 10 103 ± 3A,ns 11 106 ± 4A,* 18 102 ± 2 11 107 ± 7B,* 10 98 ± 10
Time to symptom onset (days) 10 172 ± 50A,** 11 138 ± 47A,**** 18 268 ± 38 11 62 ± 21B,**** 10 238 ± 46
Duration of disease (days) 10 45 ± 40A,ns 11 58 ± 48A,ns 18 28 ± 27 11 24 ± 18B,ns 10 45 ± 47
Time to fatal disease (days) 10 216 ± 49A,*** 11 196 ± 31A,**** 18 296 ± 33 11 86 ± 14B,**** 10 284 ± 54
Age at fatal disease stage (days) 10 319 ± 49A,*** 11 302 ± 32A,**** 18 398 ± 33 11 194 ± 15B,**** 10 381 ± 49
hSOD1 aggregates (μg/g wet weight) 5 34 ± 17A,ns n.a. 5 32 ± 11 5 17 ± 3B,** 5 32 ± 7
Loss of weights (%) 10 28 ± 9A,ns 11 25 ± 9A,ns 18 26 ± 8 11 24 ± 5B,ns 10 21 ± 12
Fig. 3  Fiber-type grouping in end-stage mice. a, c Micrographs of 
quadriceps muscle from end-stage hSOD1G85R Tg mice inoculated 
with the human  hSOD1G127X–I or control seeds and b a 200-day-old 
C57BL/6 control mouse. The muscles were stained with an antibody 
against slow myosin and the micrographs from the end-stage mice 
shows fiber type grouping indicating denervation-induced atrophy. 
Scale bars = 50 µm
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Spread of templated hSOD1 aggregation 
along the neuraxis
Spinal cords from end-stage hSOD1G85R Tg mice inocu-
lated with both the murine and human  hSOD1G127X seeds 
contained large amounts of aggregates as analyzed by both 
the epitope-mapping assay using the 57–72 ab (Fig. 4) and 
as detergent-resistant aggregates (Table 1). In the epitope-
mapping assay, the aggregates displayed strain A patterns 
(Fig. 1c, d), comparable to those induced by the current 
(Fig. 1e) and previously reported  hSOD1G85R seeds [7]. The 
difference versus the pattern induced by a  hSOD1D90A strain 
B seed is great (Fig. 1f). We conclude that both the human 
and murine  hSOD1G127X seeds transmit strain A aggregation 
to the hSOD1G85R Tg mice. Despite the differences between 
the aggregates formed by the truncated  hSOD1G127X and the 
full-length  hSOD1G85R, the seemingly identical fibril cores 
appear to form the principal templates for aggregate growth 
(Fig. 1a, b). The mice in the various treatment groups reach 
the paralytic end stage within relatively narrow ranges of 
aggregation, but there is overall an increase in levels of end-
stage aggregates, the older the mice are (Pearson correlation 
R2 = 0.419, p < 0.0001) (Table 1; Fig. 4). The reason is not 
clear, but could perhaps be caused by impaired clearance of 
cell debris and aggregates owing to microglial senescence 
[33].
The distribution of the strain A aggregation along the 
neuraxis was analyzed in end-stage mice. In the hSOD1G85R 
Tg mice inoculated with the murine- and human-derived 
 hSOD1G127X seeds, the concentrations were essentially 
even between the spinal cord segments. The brain contained 
10–20-fold less and aggregates were sparse in cerebellum 
(Fig. 5a, b). There were no significant differences between 
the left inoculation side (closed circles) and the right side 
(open circles) (Fig. 5a, b). This is comparable to the findings 
in the previous study, in which the side distributions were 
essentially equal in the paralytic end stage, whereas in the 
presymptomatic early stages, there were more aggregates 
in the left inoculation side [7]. The distributions were 
more variable between individual mice inoculated with the 
murine and human control seeds (Fig. 5c, d), and among 
hSOD1G127X and hSOD1G85R Tg mice spontaneously devel-
oping fatal motor neuron disease (Fig. 5e, f).
The sites of symptom onsets differed between the mice 
inoculated with  hSOD1G127X seeds and the control-inocu-
lated and non-inoculated groups (p < 0.02 for all compari-
sons, two-sided Fisher´s exact test). All 17 hSOD1G85R Tg 
mice inoculated with the murine  hSOD1G127X seed, and 
which were followed until onset or the end stage (c.f. Figs. 2, 
Table 2  Loss of motor neurons in inoculated mice
The table shows data for mice investigated by immunohistochemistry with an antibody directed at ChAT. Data are shown as mean ± SD. The 
p-values denote the significance of differences between end-stage  hSOD1G127X seed-inoculated mice (n = 20) and aged-matched (~ 300 days) 
asymptomatic non-inoculated  hSODG85R Tg mice (n = 12). The numbers given are the mean number of ChAT-positive profiles larger than 
150 µm2 per section investigated. Usually four sections in the lumbar and cervical segments and six in the thoracic segment were investigated. 
The mean profile areas of remaining Chat-positive cells were significantly smaller in the inoculated end-stage mice
Mean number of cells per section Mean profile areas (µm2)
Human 
 hSOD1G127X-seed 
inoculated mice
Non-inoculated 
 SOD1G85R Tg mice
p value Human 
 hSOD1G127X-seed 
inoculated mice
Non-inoculated 
 SOD1G85R Tg mice
p value
Cervical ventral horn 9.7 ± 4.6 13.0 ± 3.2 0.032 285 ± 72 422 ± 65 0.0001
Thoracic ventral horn 3.5 ± 1.6 5.2 ± 1.6 0.0063 270 ± 37 347 ± 67 0.003
Lumbar ventral horn 4.6 ± 2.7 6.2 ± 2.3 0.029 306 ± 89 437 ± 69 0.0003
Fig. 4  Content of strain A aggregates in whole spinal cords of inocu-
lated and non-inoculated hSOD1G85R Tg mice analyzed with binary 
epitope mapping. Triangles (triangle), crosses (cross) and circles 
(unfilled circle) indicate non-symptomatic, symptomatic and end-
stage mice, respectively. Blue, violet, green, and red symbols indicate 
hSOD1G85R Tg mice inoculated with the mouse  hSOD1G127X (blue 
unfilled triangle, blue unfilled cross, blue unfilled circle), human 
 hSOD1G127X I (purple unfilled triangle, purple unfilled cross, purple 
unfilled circle), mouse control (green unfilled triangle, green unfilled 
circle) and human control (red unfilled triangle, red unfilled circle) 
seeds, respectively. Gray indicates non-inoculated mice (gray unfilled 
triangle, gray unfilled circle) (lifespans minus 102 days, the mean age 
at which the inoculations took place). The shaded area indicates blank 
reactions
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4), showed paralysis onsets in the hind legs. Of 22 mice 
inoculated with the human  hSOD1G127X I and II seeds, 21 
had distinct hind leg onsets and 1 combined hind leg/foreleg 
onset (the two mice with lifespans equal to or longer than 
the mean lifespans of the human control-inoculated or the 
non-inoculated mice were excluded from this analysis, c.f. 
Fig. 2c). Of the 28 human- and murine control-inoculated 
mice, 15 had hind leg onsets and 13 had combined hind leg 
and foreleg or foreleg onsets. Finally, among 13 monitored 
non-inoculated  hSOD1G85R mice, 8 had hind leg onsets and 
5 had combined hind leg/foreleg or foreleg onsets.
Histopathology
Using the 131–153 Mo-Ab, no hSOD1 labeling was seen 
in ~ 200-day-old non-inoculated control hSOD1G85R Tg mice. 
The findings varied in-between different ~ 300-day-old control 
mice with half of them (7/13) showing no labeling at all and 5 
of the 13 showing only sparse labeling, mainly consisting of 
neuropil threads. Motor neuron somal staining was in these 
mice mainly seen at lumbar levels (Fig. 5b, e, h, k). One of the 
13 mice, 309-day-old and showing early hind leg symptoms, 
displayed extensive staining in both neuronal somata and neu-
ropil threads at all levels (data not shown) comparable to the 
findings in end-stage hSOD1G85R Tg mice (e.g., Fig. 6f, i, l).
Albeit a small individual variation in-between differ-
ent end-stage hSOD1G85R Tg mice inoculated with the 
human  hSOD1G127Xseeds (~ 300-day old) were seen, no 
consistent differences existed between  hSOD1G127X–I or 
 hSOD1G127X–II seeds when analyzed using the 131–153 
Mo-Ab. At all levels, there was extensive occurrence of neu-
ropil threads and small granular somal inclusions (Fig. 6a, d, 
g, j). Noteworthy is that not all motor neurons showed inclu-
sions. There were fewer threads in the brain stem, where the 
highest numbers were seen in the dorsal part of the medulla 
oblongata (Fig. 6J). No somatic granular inclusions were 
seen in the cortex, and only in one of eight investigated ani-
mals were neuropil threads seen there (not shown).
The findings both with regard to neuropil threads and 
soma inclusions as seen with the 131–153 Mo-Ab in end-
stage hSODG85R Tg mice inoculated with the human control 
seed preparation (~ 400-day-old) (Fig. 6c, f, i, l) were com-
parable to those in the non-inoculated end-stage hSOD1G85R 
Tg mice (~ 400-day-old) (Fig. 6p–r) and marginally less than 
seen in the human  hSOD1G127X-seed inoculated mice. Thus, 
the human control seed or the surgical trauma do not seem to 
have any effect on end-stage aggregate accumulation.
The amount of threads in the spinal cord of the end-
stage human  hSOD1G127X-1 seed-inoculated mice (~ 300-
day old) (Fig. 6a, d, g) exceeded that of the 100-day-older 
end-stage human control-inoculated hSOD1G85R Tg mice 
(Fig. 6c, f, i), while the amount of threads in the brainstem 
was higher in the latter (Fig. 6l). Somas with small granular 
inclusions were generally more numerous in the end-stage 
human control-inoculated hSOD1G85R Tg mice (Fig. 6l). The 
occurrence of threads in the human  hSOD1G127X-1 seed-
inoculated animals seems to be a late phenomenon, since in 
onset and pre-onset such mice threads were hardly seen at 
all (not shown).
It has previously been reported that hSOD1 inclusions 
are abundant in astrocytes in the hSOD1G85R Tg model 
[8]. To examine astrocyte aggregate pathology in the cur-
rent study, we utilized double-labeling confocal laser 
immunohistochemistry using the 131–153 Ch-Ab and 
an antibody directed against the astrocytic marker GFAP 
(Fig. 6m–o). We found that only few of the SOD1 inclu-
sions in end-stage hSOD1G85R Tg mice inoculated with 
the human  hSOD1G127X-1 seed (~ 300-day-old) were asso-
ciated with astrocytes (Fig. 6m), with the major propor-
tion either freely located in the neuropil or within motor 
neurons. In age-matched non-inoculated  hSOD1G85R Tg 
mice (~ 300-day old), almost none of the few threads and 
granular small inclusions immunopositive for SOD1 were 
associated with astrocytes (Fig. 6n). Finally, in end-stage 
human control-inoculated hSOD1G85R Tg mice (~ 400-day-
old), the degree of association of granular hSOD1 inclusions 
with astrocytes appeared to be comparable to that in end-
stage  hSOD1G127X-1 seed-inoculated mice (~ 300-day-old) 
(Fig. 6o). Overall, the astrocyte hSOD1 pathology appeared 
to be less advanced in our current hSOD1G85R Tg strain than 
in the original strain [8].
Discussion
The present study provides evidence for the presence of 
hSOD1 aggregates with prion-like properties in the spi-
nal ventral horn from a patient carrying the hSOD1G127X 
mutation. The two different patient-derived aggregate seed 
preparations both transmitted a premature fatal motor neu-
ron disease with hallmarks of human ALS: focal onset of 
Fig. 5  Distribution of strain A hSOD1 aggregation along the neu-
raxis in individual end-stage Tg mice. The aggregates were analyzed 
with binary epitope mapping using the 57–72 Ra-Ab. The levels in 
the segments were normalized against the levels in the lumbar spinal 
cord. Note the change in scale for brain and cerebellum. The results 
for individual mice are presented in different colors to improve dis-
tinction. a, d Results for hSOD1G85R Tg mice inoculated with indi-
cated seeds. In a, b, and d only the left (inoculation side, closed cir-
cles) or right halves (open circles) of the neuraxes were analyzed. 
In b, results for the two human  hSOD1G127X-I seed-inoculated mice 
with lifespans equal to or longer than the mean survivals of the 
human control-inoculated and the non-inoculated mice are labeled 
(cross) (c.f. Fig. 2b). e, f Results for non-inoculated hSOD1G127X and 
hSOD1G85R Tg mice
◂
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progressive paralysis, loss of motor neurons and wasting. 
Concomitantly aggregation of  hSOD1G85R developed in the 
inoculated mice, which spread all along the neuraxis. The 
aggregates in end-stage hSOD1G127X Tg mice had a strain 
A-like core structure and the induced aggregates displayed 
strain A patterns (Fig. 1c–e) [7]. This suggests that the 
aggregation transmitted by the murine  SOD1G127X seed was 
templated. The human  hSOD1G127X seed also induced strain 
A  hSOD1G85R aggregation, but since the inducing aggre-
gates could not be profiled, we cannot draw any firm conclu-
sions regarding templating. Of note, induced aggregation 
in hSOD1G85R Tg mice seems to replicate the structure of 
Fig. 6  Histopathology of 
end-stage inoculated and 
asymptomatic non-inoculated 
hSODG85R Tg mice. a–l Sections 
were stained with the 131–153 
Mo-Ab. For the non-inoculated 
300-day-old control mice (mid-
dle column), a typical picture 
for the five mice showing sparse 
labeling is shown. In seven, no 
labeling was found and in one, 
the staining was comparable to 
that of end-stage mice. Note that 
while non-inoculated 300-day-
old hSOD1G85R Tg mice almost 
entirely show thread-like immu-
noreactivity (b, e, h, and k), the 
end-stage inoculated mice show 
widespread granular reactivity 
in motor neurons somas as well 
as neuropil threads (a, c, d, f, 
g, i, j, l). m–o Sections were 
stained with the 131–153 Ch-Ab 
(green) and an antibody against 
GFAP (red). Yellow arrows 
indicate colocalization of mis-
folded SOD1 and GFAP. Note 
the large difference between 
 hSOD1G127X-I seed-inoculated 
(m) and age-matched control 
animals (n). p–r sections 
from end stage non-inoculated 
hSOD1G85R Tg mice stained 
with the 131–153 Mo-Ab. Scale 
bars = 10 µm
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the inducing species: strain B aggregates from hSOD1D90A 
Tg mice induce formation of strain B aggregates which do 
not arise spontaneously in hSOD1G85R Tg mice (Fig. 1f) [6, 
7]. Further studies are needed to address the mechanisms 
by which the hSOD1 aggregation spreads in the CNS and 
causes the fatal neurotoxicity.
Aggregates of disease-relevant proteins have shown seed-
ing effects in other models of neurodegenerative disease [11, 
12, 26, 28, 29]. The relevance of the findings for the diseases 
in humans has, however, been questioned [13, 36]. In some 
cases, the induced pathology poorly mimics the modeled 
human disease, and the amounts of aggregates in the seeds 
and levels of expression of the disease-relevant proteins in 
the animals are considered unrealistically high. It is also 
suggested that the protein aggregation is related to specific 
vulnerabilities of subsets of neurons and might mainly occur 
cell autonomously in these.
In the current study, most of these concerns have been 
addressed. (1) As in humans, the fatal disease in hSOD1G85R 
Tg mice has a middle-age onset, and demonstrates all the 
major hallmarks of human ALS. (2) The concentration of 
the  hSOD1G85R protein in the recipient mice is no higher 
than those of the endogenous murine SOD1 or hSOD1 in 
the human CNS [8, 21]—although the proportion that is 
disordered is higher [38, 39]. (3) The amounts of  SOD1G127X 
aggregates in the 1-µl inoculates were minute: 0.14–0.07 ng. 
This is around 500 times less than the amount of murine 
or human SOD1 in the same volume of spinal cord tissue 
from controls [17, 22], and ~ 30 times less than the amount 
of aggregated  hSOD1G127X present in 1-µl (mg) ventral 
horn from patients carrying the hSOD1G127X mutation [19, 
20]. Finally, the amounts of  hSOD1G85R aggregates in end-
stage mice were > 30,000 times greater than the amounts 
of  hSOD1G127X aggregates that were inoculated. Thus, the 
seeding efficiency of the patient-derived  hSOD1G127X aggre-
gates was extremely high, and they transmitted disease to 
the Tg mice at levels that were much lower than those found 
in motor areas of  hSOD1G127X patients. (4) The nature of 
the selective vulnerability of motor areas to SOD1-induced 
toxicity is still poorly understood. We have previously 
reported on two properties that would enhance the vulner-
ability to aggregation. Spinal cords from Tg model mice 
show a marked enrichment of disordered hSOD1 monomers 
[38, 39], which are the necessary substrates for nucleation 
and growth of aggregate fibrils [10, 16, 25]. Autophagy is 
found to be important for retarding hSOD1 aggregation in 
the transgenic models, and spinal motor areas in humans 
have apparently a low inherent such capacity [35]. These two 
properties could conceivably enhance autonomous hSOD1 
aggregation in cells compromised by other neurotoxic mech-
anisms, but would certainly also increase the risk of stochas-
tic initiation and subsequent prion-like spread of hSOD1 
aggregation preferentially in the motor areas. The patterns 
of spontaneous hSOD1 aggregation in the murine models 
support the latter possibility. Here, and previously, we have 
shown that strain A and B hSOD1 aggregate seeds initiate 
templated hSOD1 aggregations which spread from the site 
of inoculation, from which area also the initial motor symp-
toms derive [7]. In hSOD1G85R Tg mice that spontaneously 
develop disease or are inoculated with human or murine 
control seeds, the aggregation seems to initiate and spread 
from random positions along the spinal cord, with symptom 
onsets related to the segments with highest aggregate levels 
in the individual mice [7].
We conclude that hSOD1 aggregate seeds prepared 
from spinal ventral horn from a patient carrying a hSOD1 
mutation when inoculated in hSOD1-expressing mice ini-
tiated spreading hSOD1 aggregation concomitantly with 
fatal motor neuron disease. The potency of the seeds was 
extremely high, and disease was initiated in the Tg mice 
by levels of  hSOD1G127X aggregates much lower than those 
found in the human motor system. Our results suggest that 
prion-like spread of hSOD1 aggregation could be the pri-
mary pathogenic mechanism, not only in hSOD1 Tg models, 
but also in hSOD1-induced ALS in humans.
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